Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 micrograms octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.
Lee
E J
EJ
Department of Internal Medicine, Yong Dong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kim
K R
KR
Lim
S K
SK
Lee
H C
HC
Kim
D I
DI
Kim
S H
SH
Huh
K B
KB
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010903:Pituitary Gland, Anterior; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013972:Thyrotropin / Q000378:metabolism*
D013972:Thyrotropin; D015282:Octreotide